-
CGeneTech Secures RMB 100 Million in Series C Financing to Advance Drug Commercialization and Clinical Pipeline
•
CGeneTech (Suzhou, China) Co., Ltd., a biopharmaceutical company based in China, has reportedly secured a Series C financing round totaling RMB 100 million, led by Tongren Boda Investment. The capital raised will be strategically allocated towards the commercial-scale manufacturing and marketing efforts for its flagship product, centagliptin, a Category 1…
-
China’s Supreme Court Deals Blow to Sanofi’s Aubagio, Confirms Patent Cancellation
•
BEIJING—In a recent development for the pharmaceutical industry, Sanofi’s multiple sclerosis therapy Aubagio (teriflunomide) has suffered a significant setback in China. According to the latest information, three decisions from China’s Supreme Court in May 2024 have upheld the cancellation of Sanofi’s formulation patents for Aubagio tablets, as requested by an…
